Tags

Type your tag names separated by a space and hit enter

Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.

Abstract

PURPOSE

To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily to white Greeks with primary open-angle glaucoma and ocular hypertensive patients.

DESIGN

A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM.

PARTICIPANTS

Thirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled.

INTERVENTIONS

Latanoprost 0.005% given every evening and TDFC twice daily.

MAIN OUTCOME MEASURES

The primary efficacy variable was diurnal intraocular pressure.

RESULTS

Thirty-three patients completed the study. On the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05). Individual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006). Eighteen patients overall preferred latanoprost versus 2 patients for the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009). Despite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma.

CONCLUSIONS

This study indicates that the 24-hour diurnal intraocular pressure is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in primary open-angle glaucoma and ocular hypertensive patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.

    , , ,

    Source

    Ophthalmology 110:7 2003 Jul pg 1357-60

    MeSH

    Adult
    Antihypertensive Agents
    Circadian Rhythm
    Cross-Over Studies
    Drug Administration Schedule
    Drug Therapy, Combination
    Female
    Glaucoma, Open-Angle
    Humans
    Intraocular Pressure
    Latanoprost
    Male
    Middle Aged
    Ocular Hypertension
    Prostaglandins F, Synthetic
    Safety
    Single-Blind Method
    Sulfonamides
    Thiophenes
    Timolol
    Treatment Outcome

    Pub Type(s)

    Clinical Trial
    Comparative Study
    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    12867391

    Citation

    Konstas, Anastasios G P., et al. "Twenty-four-hour Diurnal Curve Comparison of Commercially Available Latanoprost 0.005% Versus the Timolol and Dorzolamide Fixed Combination." Ophthalmology, vol. 110, no. 7, 2003, pp. 1357-60.
    Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110(7):1357-60.
    Konstas, A. G., Papapanos, P., Tersis, I., Houliara, D., & Stewart, W. C. (2003). Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology, 110(7), pp. 1357-60.
    Konstas AG, et al. Twenty-four-hour Diurnal Curve Comparison of Commercially Available Latanoprost 0.005% Versus the Timolol and Dorzolamide Fixed Combination. Ophthalmology. 2003;110(7):1357-60. PubMed PMID: 12867391.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. AU - Konstas,Anastasios G P, AU - Papapanos,Panayiotis, AU - Tersis,Ioannis, AU - Houliara,Dimitra, AU - Stewart,William C, PY - 2003/7/18/pubmed PY - 2003/7/29/medline PY - 2003/7/18/entrez SP - 1357 EP - 60 JF - Ophthalmology JO - Ophthalmology VL - 110 IS - 7 N2 - PURPOSE: To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily to white Greeks with primary open-angle glaucoma and ocular hypertensive patients. DESIGN: A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM. PARTICIPANTS: Thirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled. INTERVENTIONS: Latanoprost 0.005% given every evening and TDFC twice daily. MAIN OUTCOME MEASURES: The primary efficacy variable was diurnal intraocular pressure. RESULTS: Thirty-three patients completed the study. On the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05). Individual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006). Eighteen patients overall preferred latanoprost versus 2 patients for the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009). Despite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma. CONCLUSIONS: This study indicates that the 24-hour diurnal intraocular pressure is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in primary open-angle glaucoma and ocular hypertensive patients. SN - 0161-6420 UR - https://www.unboundmedicine.com/medline/citation/12867391/Twenty_four_hour_diurnal_curve_comparison_of_commercially_available_latanoprost_0_005_versus_the_timolol_and_dorzolamide_fixed_combination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(03)00404-4 DB - PRIME DP - Unbound Medicine ER -